Open AccessHouse dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma
Author(s) -
Hisashi Tanida,
Takayasu Nomura,
Yuto Kondo,
Yasutaka Hirabayashi,
Jun Wakatsuki,
Shinji Saitoh
Publication year - 2021
Publication title -
asian pacific journal of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 33
ISSN - 0125-877X
DOI - 10.12932/ap-051220-1009
Subject(s) - medicine , slit , asthma , house dust mite , sublingual immunotherapy , cohort , adverse effect , allergy , pediatrics , allergic asthma , pyroglyphidae , allergen , immunology , genetics , biology
: Despite the reported clinical effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in pediatric patients, the risk of treatment remains unclear in pediatric patients with allergic asthma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom